Effects of carbamazepine/oxycodone coadministration in the treatment of trigeminal neuralgia

Annals of Pharmacotherapy

Volumn 45, Issue 6, 2011, Pages 33-

  Siniscalchi, Antonio ^a   Gallelli, Luca ^b   Avenoso, Tiziana ^b   Squillace, Aida ^b   de Sarro, Giovambattista ^b  

^a Annunziata Hospital   (Italy)

^b UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

Author keywords

Carbamazepine; Oxycodone; Trigeminal neuralgia

Indexed keywords

CARBAMAZEPINE; OXYCODONE;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; ATAXIA; CASE REPORT; DIPLOPIA; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; FACE PAIN; FEMALE; HUMAN; IDIOPATHIC DISEASE; MOUTH PAIN; NEUROLOGIC EXAMINATION; NEURORADIOLOGY; PRIORITY JOURNAL; TRIGEMINUS NEURALGIA;

ANALGESICS, NON-NARCOTIC; ANALGESICS, OPIOID; CARBAMAZEPINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MIDDLE AGED; OXYCODONE; TREATMENT OUTCOME; TRIGEMINAL NEURALGIA;

EID: 79958830603     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1Q013     Document Type: Article

References (31)

1. Prasad S, Galetta S. Trigeminal neuralgia: historical notes and current concepts. Neurologist 2009;15:87-94.
2. Baron R, Binder A, Wasner G. Neuropathic pain: diagnosis, pathophysiological mechanisms, and treatment. Lancet Neurol 2010;9:807-19.
3. Gronseth G, Cruccu G, Alksne J, et al. Practice parameter: the diagnostic evaluation and treatment of trigeminal neuralgia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology and the European Federation of Neurological Societies. Neurology 2008;71:1183-90.
4. Attal N, Cruccu G, Baron R, et al. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol 2010;17: 1113-e88.
5. Thun J, Persson AK, Fried K. Differential expression of neuronal voltage- gated sodium channel mRNAs during the development of the rat trigeminal ganglion. Brain Res 2009;1269:11-22.
6. Jones AK, Kitchen ND, Watabe H, et al. Measurement of changes in opioid receptor binding in vivo during trigeminal neuralgic pain using (11C) diprenorphine and positron emission tomography. J Cereb Blood Flow Metab 1999;19:803-8.
7. Baron R, Binder A, Wasner G. Neuropathic pain: diagnosis, pathophysiological mechanisms, and treatment. Lancet Neurol. 2010;9:807-19.
8. Kalso E, Vainio A. Morphine and oxycodone hydrochloride in the management of cancer pain. Clin Pharmacol Ther 1990;47: 639-64.
9. Hanks GW, Hawkins C. Agreeing a gold standard in the management of cancer pain: the role of opioids. In: Hillier R, Finlay I, Welsh J, Miles A, eds. UK key advances in clinical practice series 2000. The effective management of cancer pain. London: Aesculapius Medical Press, 2000:57- 75.
10. Bruera E, Belzile M, Pituskin E, et al. Randomised double blind crossover trial comparing safety and efficacy of oral controlled release oxycodone with controlled release morphine in patients with cancer pain. J Clin Oncol 1998;16: 3222-9.
11. Levy MH. Pharmacologic treatment of cancer pain. N Engl J Med 1996; 335:1124-32
12. Hanks GW, Conno F, Cherny N, et al. Morphine and alternative opioids in cancer pain: the EAPC recommendations. Br J Cancer 2001;84:587- 93.
13. Zacny JP, Lichtor SA. Within-subject comparison of the psychopharmacological profiles of oral oxycodone and oral morphine in non-drugabusing volunteers. Psychopharmacology 2008;196:105-16.
14. Riley J, Eisenberg E, Muller-Schwefe G, Drewes AM, Arendt-Nielsn L. Oxycodone: a review of its use in the management of pain. Curr Med Res Opin 2008;24:175-92.
15. Dumas EO, Pollak GM. Opioid tolerance development: a pharmacokinetic/ pharmacodynamic perspective. AAPS J 2008;10:537-51.
16. Raffa RB, Pergolizzi JV, Segarnick DJ, Tallarida RJ. Oxycodone combinations for pain relief. Drugs Today (Barc) 2010;46:379-98.
17. Haanpää M, Attal N, Backonja M, et al. NeuPSIG guidelines on neuropathic pain assessment. Pain 2011;152:14-27.
18. Nurmikko T, Miles J, Eldridge P, Bowsher D. Treatment for trigeminal neuralgia. Pathophysiological mechanisms of trigeminal neuralgia need to be explored. BMJ 1997;314:519.
19. Siqueira SR, Alves B, Malpartida HM, Teixeira MJ, Siqueira JT. Abnormal expression of voltage-gated sodium channels Nav1.7, Nav1.3 and Nav1.8 in trigeminal neuralgia. Neuroscience 2009;164:573-7.
20. Hains BC, Waxman SG. Sodium channel expression and the molecular pathophysiology of pain after SCI. Prog Brain Res 2007;161:195-203.
21. Su X, Joshi SK, Kardos S, Gebhart GF. Sodium channel blocking actions of the kappa-opioid receptor agonist U50,488 contribute to its visceral antinociceptive effects. J Neurophysiol 2002;87:1271-9.
22. Su X, Castle NA, Antonio B, et al. The effect of kappa-opioid receptor agonist on tetrodotoxin-resistant sodium channels in primary sensory neurons. Anesth Analg 2009;109:632-40.
23. Aita M, Byers MR, Chavkin C, Xu M. Trigeminal injury causes kappa opioid-dependent allodynic, glial and immune cell responses in mice. Mol Pain 2010;6:8.
24. Tremont-Lukats IW, Megeff C, Backonja M. Anticonvulsants for neuropathic pain syndrome: mechanisms of action and place in therapy. Drugs 2000;60:1029-5.
25. Mantegazza M, Curia G, Biagini G, Ragsdale DS, Avoli M. Voltage-gated sodium channels as therapeutic targets in epilepsy and other neurological disorders. Lancet Neurol 2010;9:413-24.
26. Gatti A, Sabato AF, Occhioni R, Colini Baldeschi G, Reale C. Controlled- release oxycodone and pregabalin in the treatment of neuropathic pain results of a multi center Italian study. Eur Neurol 2009;61:129-37.
27. Maneuf YP, Luo ZD, Lee K. Alpha2delta and the mechanism of action of gabapentin in the treatment of pain. Semin Cell Dev Biol 2006;17: 565-70.
28. Gajraj NM. Pregabalin: Its pharmacology and use in pain management. Anesth Analg 2007;105:1805-15.
29. Siniscalchi A, Gallelli L, De Sarro GB. Use of antiepileptic drugs for hyperkinetic movements disorders. Curr Neuropharmacol 2010;8:359-66.
30. Ross FB, Smith MT. The intrinsic antinociceptive effects of oxycodone appear to be kappa-opioid receptor mediated. Pain 1997;73:151-7.
31. Capuano A, De Corato A, Treglia M, et al. Peripheral antinociceptive effects of low doses of naloxone in an in vivo and in vitro model of trigeminal nociception. Neuropharmacology 2010;58:784-92.